Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.93 USD
+0.16 (9.04%)
Updated May 13, 2024 04:00 PM ET
After-Market: $1.93 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
PACB 1.93 +0.16(9.04%)
Will PACB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PACB
PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up
Pacific Biosciences (PACB) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
Other News for PACB
Stocks with more than 10% short interest - Finviz Screener
PacBio price target lowered by $6 at Morgan Stanley, here's why
Scotiabank Sticks to Its Buy Rating for Pacific Biosciences (PACB)
PacBio price target lowered by $4.50 at Piper Sandler, here's why
Expert Outlook: Pacific Biosciences Through The Eyes Of 10 Analysts